HDAC9 and neuroblastoma: Therefore, a consideration of both the desired outcome of HDAC inhibition, as well as an understanding of the specificity required to achieve this outcome, will be required for the development of effective combination therapies, which is a standard therapeutic approach required for neuroblastoma patients (Fletcher et al., 2018).